PROCESS FOR PREPARING ACIDS VIA ALPHA-CHLOROEPOXY ESTERS

Abstract: This invention relates to a method for preparing certain acids of formula (I) via a chloroepoxy ester, which are useful as phosphodiesterase 4 inhibitors.

Description: Process for Preparing Acids via Alpha-Chloroepoxy Esters Area of the Invention This invention relates to a method for prepaπng certain acids which are useful as phosphodiesterase 4 inhibitors More specifically this invention relates to a method for converting cyclohexanones to cyclohexanoic acids via an alpha-haloepoxy ester Background of the Invention The process of this invention relates to making compounds which are useful in treating diseases modulated by the isoforms of the phosphodiesterase 4 enzyme The alpha- haloepoxy esters used in this process are unique compounds and useful in making acids which are known PDE 4 inhibitors which are useful, among other things, for treating pulmonary diseases such as chronic obstructive pulmonary disease (COPD) and asthma The compounds which are prepared by the methods of this invention and the intermediates disclosed herein are disclosed and descπbed in the likes of U S patent 5,554,238 issued 03 September, 1996 That patent is incorporated heπn by reference in full Those compounds, particularly the 4-cyanocyclohexanoιc acids, have marked effects on neutrophil activity, inhibiting neutrophil chemotaxis and degranulation in vitro In animal models, those compounds reduce neutrophil extravasation from the circulation, pulmonary sequestration and the edematous responses to a number of inflammatory insults in vivo They have been found to be useful in treating COPD in humans, and possibly in other mammalian species which suffer from COPD Herein there is provided a method for prepaπng certain of the phenyl-substituted cyclohexanoic acids, particularly those disclosed in US patent 5,554,238 by starting with a cyclohexan-1-one and proceeding via a novel intermediate, an alpha-haloepoxy ester, to the acid analog of the ketone starting mateπal Summary of the Invention In a first aspect this invention relates to a process for prepaπng substituted cyclohexanoic acids of formula (I) where R a is a carbon-containmg group optionally linked by oxygen, sulfur or nitrogen to the cyclohexyl nng and j is 1-10, and R and R* are independently but not simultaneously hydrogen or C(0)E where E is OR 14 or SR 14 , which process compπses treating an epoxide of formula A with dimethyl sulfoxide and an alkali metal salt wherein formula A is wherein E is OR14 or SR14 where R14 is hydrogen or alkyl of 1-6 carbon atoms, R a is the same as defined for Formula (I), and Y is Br, Cl, F or I More particularly this invention relates to a process for preparing compounds of formula IA wherein R, is -(CR4R5)nC(0)0(CR4R5) m R6, -(CR4R5)nC(0)NR4(CR4R 5 ) m R6, -(CR4R5) n O(CR4R5) m R6, or -(CR4R5) r R6 wherein the alkyl moieties are unsubstituted or substituted with one or more halogens, m is 0 to 2, R4 and R5 are independently selected hydrogen or C\-2 alkyl, R6 is hydrogen, methyl, hydroxyl, aryl, halo substituted aryl, aryloxyCi-3 alkyl, halo substituted aryloxyCi-3 alkyl, indanyl, indenyl, Cη.\ \ polycycloalkyl, tetrahydrofuranyl, furanyl, tetrahydropyranyl, pyranyl, tetrahydrothienyl, thienyl, tetrahydrothiopyranyl, thiopyranyl, C3-6 cycloalkyl, or a C4-6 cycloalkyl containing one or two unsaturated bonds, wherein the cycloalkyl or heterocyclic moiety is unsubstituted or substituted by 1 to 3 methyl groups, one ethyl group, or an hydroxyl group, provided that: a) when R6 is hydroxyl, then m is 2; or b) when R is hydroxyl, then r is 2 to 6; or c) when R6 is 2-tetrahydropyranyl, 2-tetrahydrothiopyranyl, 2-tetrahydrofuranyl, or -tetrahydrothienyl, then m is 1 or 2; or d) when R6 is 2-tetrahydropyranyl, 2-tetrahydrothiopyranyl, 2-tetrahydrofuranyl,or 2-tetrahydrothienyl, then r is 1 to 6; e) when n is 1 and m is 0, then R6 is other than H in -(CR4R5) n O(CR4R5) m R6; X is YR2; Y is O; X2 is O; R2 is -CH3 or -CH2CH3, optionally substituted by 1 or more halogens; R and R* are hydrogen or C(0)E wherein one of R or R* is always hydrogen and the other is always C(0)E where E is OR14, or SR14; W is a bond or is alkenyl of 2 to 6 carbon atoms or alkynyl of 2 to 6 carbon atoms; when W is a bond R' is hydrogen, halogen, C1 -4 alkyl, CH2NHC(0)C(0)NH2, halo-substituted C1-4 alkyl, CN, ORs, CH2OR8, NRsRlO, CH2NR8R10, C(Z")H, C(0)OR8, or C(O)NRgRl0; and when W is alkenyl of 2 to 6 carbon atoms or alkynyl of 2 to 6 carbon atoms then R' is COOR 14, C(0)NR4R 14 or R7 ; R7 is -(CR4R5)qRi2 or C 1.5 alkyl wherein the Ri 2 or C 1.5 alkyl group is unsubstituted or substituted one or more times by: methyl or ethyl unsubstituted or substituted by 1-3 fluorines, or -F, -Br, -Cl, -N0 , - R I QRI \, -C(0)Rs, -CO2R8, -0(CH 2 ) 2 -4θR8> -0(CH 2 ) q R8, -CN, -C(O)NRι 0 Rl 1, -O(CH 2 ) q C(O)NRι 0 Rl 1, - 0(CH 2 ) q C(0)R 9 , -NRιoC(O)NRιoRl 1, -NRι 0 C(O)Rι 1, -NRι 0 C(O)OR 9 , -NRιoC(0)Ri3, -C(NRιo)NRιoRl l, -C(NCN)NRιoRn, -C(NCN)SR9, -NRιoC(NCN)SR9 , -NRιoC(NCN)NRιoR- i, -NRiθS(0)2R9, -S(0) m 'R9, -NRιoC(O)C(O)NRιoRl l, -NRioC(O)C(O)Rιo, or R 13 ; q is 0, 1, or 2; R12 is R13, C3-C7 cycloalkyl, or an unsubstituted or substituted aryl or heteroaryl group selected from the group consisting of (2-, 3- or 4-pyridyl), pyrimidyl, pyrazolyl, ( 1- or 2-imidazolyl), pyπolyl, piperazinyl, piperidinyl, morpholinyl, furanyl, (2- or 3-thienyl), quinolinyl, naphthyl, and phenyl; Rg is independently selected from hydrogen or R9; R9 is Cι_4 alkyl optionally substituted by one to three fluorines; R[ l is hydrogen, or C 1.4 alkyl unsubstituted or substituted by one to three fluorines, or when RJ O and Ri 1 are as NRi øRl 1 they may together with the nitrogen form a 5 to 7 membered πng compπsed of carbon or carbon and one or more additional heteroatoms selected from O, N, or S, R 13 is a substituted or unsubstituted heteroaryl group selected from the group consisting of oxazohdinyl, oxazolyl, thiazolyl, pyrazolyl, tπazolyl, tetrazolyl, lmidazolyl, lmidazohdinyl, thiazolidmyl, isoxazolyl, oxadiazolyl, and thiadiazolyl, and where Rπ is substituted on R) 2 or R )3 the πngs are connected through a carbon atom and each second R πng may be unsubstituted or substituted by one or two Cj_2 alkyl groups unsubstituted or substituted on the methyl with 1 to 3 fluoro atoms, and R14 is hydrogen or Cι _6 alkyl, which process compπses treating an epoxide of formula A with dimethyl sulfoxide and an alkali metal salt wherein formula A is wherein X, Rι X2 > W, E, R', and R14 are the same as defined for Formula (IA), and Y is Br, CI, F or I In a second aspect this invention relates to a process for making the epoxide of Formula (A) where R1X2. X. W, R' and Y are the same as for Formula (IA) and the R14 in E is C\. βalkyl, which process compπses treating a ketone of Formula (B) with an alkyldihaloacetate or alkyldihalothioacetate in a polar aprotic solvent and optionally saponifying the resulting epoxy ester or thioester, wherein X, jX2. and R' are the same as in Formula (A). In a further aspect, this invention relates to a method for enriching the cis form of Formula (I) or (IA) where one of R or R* is C(0)OH or C(0)SH and the other is hydrogen in a mixture of cis and trans isomers. The method comprises esterifying the acid or thioacid or converting them to a mixed anhydride, if they are not already in that form, then treating the ester, etc, with an alkoxide base for a time sufficient to give a ratio of cis to trans isomers which is at least 4: 1, perferably 7: 1 or greater. In yet another aspect, this invention relates to the haloepoxy acids and haloepoxy esters, thioesters and mixed anhydrides of formula A. Detailed Description of the Invention This invention provides a means for preparing cyclohexanoic acids. In particular it relates to a method for preparing cyclohexanoic acids which are phosphodiesterase 4 inhibitors as more fully disclosed in U.S. patent 5,554,238. The invention can also be used to prepare any cyclohexanoic acid and for enriching the cis form of a cyclohexanoic acid in a mixture of cis and trans isomers. As regards the preferred substituents on Formulas (IA), (A) and (B), for R\ they are CH2-cyclopropyl or C4.6 cycloalkyl. Preferred R2 groups are a Ct-2 alkyl unsubstituted or substituted by 1 or more halogens. The halogen atoms are preferably fluorine and chlorine, more preferably fluorine. More preferred R2 groups are those wherein R2 is methyl, or a fluoro-substituted alkyl group, specifically a Ct-2 alkyl such as a -CF3, -CHF2, or -CH2CHF2. Most prefeπed are the -CHF2 and -CH3 moieties. Most preferred are those compounds wherein R\ is -CH2-cyclopropyl, cyclopentyl, 3-hydroxycyclopentyl, methyl or CHF2 and R2 is CF2H or CH3. Preferably the R14 group will be methyl, ethyl or hydrogen. In formula (IA), methyl is the most preferred R14 group, and in Formula (I), it is methyl or hydrogen. Particularly prefeπed are those compounds where R1 is cyclopentyl and R2 is CH3. As regards W, the prefeπed embodiment is where W is a bond, ethylenyl, or -C≡C-. When W is a bond, the prefeπed R' group is CN. And when W is ethylenyl, -C≡C- the prefeπed R' group is hydrogen. The most prefeπed compound of Foπnula (IA) made by the process of this invention is c/s-[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexane- 1-carboxylic acid]. In regards to the epoxides, the lower alkyl chloroepoxy esters, thioesters and their coπesponding acids are prefeπed. Methyl and ethyl are the most prefeπed ester-forming groups. The most perfeπed epoxides are methyl 2-chloro-6-cyano-6-[3-(cyclopentyloxy)-4- methoxyphenyl]-l-oxaspiro[2.5]octane-2-carboxylate and 2-chloro-6-cyano-6-[3- (cyclopentyloxy)-4-methoxyphenyl]-l-oxaspiro[2.5]octane-2-carboxylic acid. Scheme I illustrates the conversion of a ketone of Formula (B) to the ester or acid of Formula (IA). Scheme 1 (1-1) (1-2) NaOMe, H 2 0 (1-2) (1-3) C0 2 H ( 1-3) (1-4) In compound 1-4, R and R* are hydrogen or C(0)OH, but R and R* are not both hydrogen or C(0)OH simultaneously. The ketone starting material (1-1) can be prepared by the methods set out in U.S. patent 5,554,238 or 5,449,686. Forming the epoxide (1-2) is accomplished by treating the ketone with 1.1 to 2 equivalents of a lower alkyldihaloacetate using a polar non-protic solvent. "Lower alkyl" here means an alkyl radical having 1-6 carbon atoms. It is prefeπed to use about 1.5 equivalents of the acetate, and teterahydrofuran as the solvent. First the ketone (1-1) and the actetate are dissolved in the solvent. This solution is cooled to between -10 and +10 °C and an organic base is added in a molar excess (e.g. 1.1 to 2 equivalents, preferably about 1.5 equivalents). Herein an alkali metal t-butoxide is the prefeπed base, particularly potassium tert-butoxide. The temperature is kept at within the -10 to +10 °C range during the addition of the base and for some short period, 10 minutes to 45 minute thereafter. Product (1-2) is recovered by conventional means. The ester (1-2) is then saponified using a base. This can be accomplished by any number of bases using conventional techniques. Herein this reaction is effected by treating the α-chloroepoxyester with sodium methoxide using a low molecular-weight alcohol and water as the solvent. A substantial molar excess of the base and solvent is used. For example a 5-fold excess of the base can be used and about a 10-fold excess of water. The ester is charged to a reaction vessel, dissolved in the alcohol, base is added and then the water is added The reaction goes to completion rapidly at room temperature, about 5 to 30 minutes. Product, the acid, is recovered by conventional means. Since it, the α-chloroepoxy acid (1-3), is relatively unstable it is prefeπed to immediately treat the epoxide with a reactant which opens the ring to give the acid. Herein the epoxy acid (1-3) is reaπanged to give 1-4 using dimethyl sulfoxide and an alkali metal salt. Water is used as a co-solvent. The alkali metal salt may be LiCl, KG or NaCl, or the coπesponding flouride and bromide salts LiF, KF, NaF, LiBr, KBr, and NaBr. By way of more specific example, the chloroepoxy acid is dissolved in dimethyl sulfoxide and water and a small amount of a sodium chloride is added to the reaction pot which is then heated for several hours. A prefeπed set of reactants and conditions is one where about a 10-fold excess of DMSO (by weight/volume) is used to dissolve the acid and a small amount of water and a salt such as sodium chloride is added. This solution is heated to between about 125 and 175 °C for 2-5 hours; preferably the solution is heated to about 150 °C for 3.5 hours or so. This reaction gives the cyclohexanoic acid as a mixture of the cis and trans isomers in about a 1-1 ratio. Enrichment of the cis isomer in the mixture of cis and trans isomers obtained from the just-described reaction is accomplished by activating it by, for example, forming an ester or mixed anhydride, and then treating the ester with an alkoxide base. This technique can be applied with satisfactory results to any preparation where one has a mixture of isomers and wishes to enrich the cis form of the isomer in that mixture. By way of example, the technique used here is to esterify the acid using an acid and a lower alkanol to form the ester of the alkanol. Methanol is most perfeπed. This mixture is then treated with f-butanol and its alkali metal salt for an extended period, for between 5 and 24 hours for example; a prefeπed time is about 12 hours. This latter step results in an enrichment of the cis form of the product; the equilibration process gives the prefeπed cis form of the acid. An alternative process is to combine the step of opening of the epoxy acid, really a decarboxylation, with the esterification step by using a lower alkanol or lower thioalkanol (1-6 carbons) as the co-solvent instead of water. The re-equilibration can be effected by adding the appropriate alcohol and its alkali metal salt to the reaction flask once the ester has been formed from the α-haloepoxy acid without isolating the ester. For example methanol rather than water can be used as the solvent for the dimethyl sulfoxide/salt reaction. If this is done, one obtains the methyl ester as the product, rather than the acid obtained when water is used as the solvent. However if methanol or another low boiling- point alkanol is used, a pressurizable reaction vessel must be employed since the solution must be heated to about 150 °C to effect the decarboxylation, at which temperature the methanol would be mostly vaporized if the reaction was run at 1 atmosphere of pressure. A prefeπed approach is to run the reaction using methanol in a pressurized container, cooling the reaction mixture to about room temperature, and adding the likes of f-butanol and its alkali metal salt to effect the coversion of the trans form to the cis isomer. By way of further illustration, but without intending to be limited in any way, the following illustrative examples are provided. Examples Example 1 Preparation of methyl 2-chloro-6-cvano-6-r3-(cyclopentyloxy)-4-methoxyphenyll- 1 - oxaspiror2.51octane-2-carboxylate ( 1) (2) A 100 mL round-bottom flask was charged with 4-cyano-4-(3-cyclopentyloxy-4- methoxyphenyl)cyclohexan-l-one (1)(4.0 g, 12.8 mmole, 1.0 eq), methyldichloroacetate (2.74 g, 1.98 mL, 19.1 mmole, 1.5 eq), and tetrahydrofuran (THF, 40 mL). The solution was cooled to 0 °C in an ice bath, then potassium tert-butoxide was added (19.1 mL, 19.1 mmole of a 1M solution in THF) while maintaining the temperature below 5 °C (about 25 minutes). The reaction was deemed complete at the end by TLC (hexanes/ethyl acetate @3/l, silica gel plates), then was poured into ethyl acetate and 5% HC1 for an extractive workup. The layers were separated and the water layer was extracted with ethyl acetate twice. The combined ethyl acetate layers were extracted with 5% sodium bicarbonate and with brine. The ethyl acetate layer was concentrated under vacuum to a yellow oil. The oil was dissolved in 3/1 hexanes/ethyl acetate and filtered through 1.5 " of flash silica gel. Concentration produced the product methyl 2-chloro-6-cyano-6-[3-(cyclopentyloxy)-4- methoxyphenyl]-l-oxaspiro[2.5]octane-2-carboxylate as a clear, colorless oil. The molecular weight and structure of the product was confirmed to be the methyl α- chloroepoxy ester by mass spec. Example 2 Preparation of 2-chloro-6-cvano-6-r3-(cvclopentyloxy)-4-methoxyphenyll-l- oxaspiror2.51octane-2-carboxylic acid (2) (3) A 50 mL flask was charged with the chloroepoxyester (2) (3.0 g, 4.77 mmole), 30 mL of methanol, sodium methoxide (5.16 g of 25 wt % solution in methanol, 23.9 mmole) and water (0.8 g, 44 mmole). The solution was stiπed for 10 minutes and the reaction was deemed complete by TLC (hexanes/ethyl acetate @3/l, silica gel plates). The reaction was poured into an addition funnel containing 100 mL of 1% HCl and 100 mL of t-butylmethyl ether. The organic layer was extracted once with water and once with brine, then was concentrated to an oil under reduced pressure. The product 2-chloro-6-cyano-6-[3- (cyclopentyloxy)-4-methoxyphenyl]-l-oxaspiro[2.5]octane-2-carboxylic acid was confirmed by mass spectral analysis. Example 3 Preparation of c/j-r4-cvano-4-(3-cvclopentyloxy-4-methoxyphenyl)cyclohexane- l- carboxylic acidl (3) (I) In this example, either R or R* can be C(0)OH; the other group must be hydrogen. Freshly prepared chloroepoxyacid (3) (2.79 mmole) was treated with dimethyl sulfoxide (7.5 mL), water (0.5 mL), and NaCl (50 mg). The solution was heated to 150 °C for 3.5 hours. The reaction was followed by HPLC (15 cm Supelcocil, ACN/water/TFA [40/60/0.1] 1.5 mL/min,215 nm UV, trans form -- at 10.6 min and cis form at 1 1.3 min). The yield was calculated using weighted assay. The yield was 59% for the two isomers in a ratio of one-to-one. Example 4 Enrichment of the Cis Isomer in a CislTrans Mixture of r4-cyano-4-(3-cvclopentyloxy-4- methoxyphenvQcvclohexane- 1 -carboxylic acid! R * = C0 2 H, R = H or R * = H, R = C0 2 H Equilibration cis form The isomeric mixture obtained in the previous step was dissolved in 10 mL of methanol. p-Toluenesulfonic acid (0.1 g) was added and the reaction was refluxed for 12 hours to form the methyl esters. The reaction was diluted with ethyl acetate and water. The layers were separated, then the organic layer was concentrated. The oil was dissolved in about 10 mL of tBuOH and then 7.5 mL of potassium r-butoxide (1M in t-BuOH) was added for the equilibration. After stirring overnight, a small sample was treated with water and the ratio of cis to trans isomers of [4-cyano-4-(3-cyclopentyloxy-4- methoxyphenyl)cyclohexane-l -carboxylic acid] was calculated as 9.6/1 by HPLC (15 cm Supelcocil, ACN/water/TFA [40/60/0.1] 1.5 mIJmin,215 nm UV, trans form at 10.6 min and cis form at 11.3 min). The reaction was quenched by adding 1% HCl and ethyl acetate to extract. The layers were separated and the organic layer was extracted once with water. The product layer was concentrated and then treated with ethyl acetate. The product was precipitated by adding about one volume of hexanes. No trans form was detected in the product. This reaction was also run using NaH under the same conditions. It gave an 8: 1 ratio of cis:trans isomers. When the same reaction was run using NaH in ethanol (methyl ester) a 7: 1 ratio was obtained. Using the ethyl ester rather than the methyl ester as the substrate, and NaH and ethanol, a 10: 1 ratio was obtained. Example 5 One-Pot Preparation of the GA[4-cvano-4-(3-cyclopentyloxy-4- methoxyphenvDcvclohexane- l -carboxylic acidl from Methyl 2-chloro-6-cvano-6-r3- (cvclopentyloxy)-4-methoxyphenyll- l-oxaspirof2.51octane-2-carboxylate Chloroepoxyester (0.72 g purified, 1.71 mmole) in methanol (5 mL) was treated with sodium methoxide (1.42 g of 25% wt solution in methanol, 6.5 mmole) and water (0.5 mL) and stiπed for 15 minutes. The reaction was quenched with t-butylmethyl ether and 1 % HCl. The bottom layer was removed, then the organic layer was washed three times with water. The organic layer was concentrated under reduced pressure, then the water was azeotroped by adding methanol and reconcentrating. Dimethylsulfoxide (7 mL), sodium chloride (0.5 g) and methanol (5 mL) were added. The contents were then heated under pressure to 150 °C for 1.5 hours. The HPLC (15 cm Supelcocil, ACN/water/TFA [40/60/0.1 ] 1.5 mL/min,215 nm UV) showed the isomeric mixture of esters and acids at 10.5/1 (esters/acids). The reaction was cooled, then 10 mL of t-BuOH and 0.20 g of t-BuOK was added The solution was stiπed overnight to give a 7/1 ratio of cislirans isomers. The reaction was worked up with 1% HCl and t- butylmethyl ether. The layers were separated and the organic layer was concentrated to an oil. The oil was dissolved in a minimum amount of warm ethyl acetate, and the product was precipitated by adding hexanes, cooled to 0 °C, then filtered. The product was a light tan solid; no trans isomer was detected.

Claims: What is claimed is: 1. A process for preparing substituted cyclohexanoic acids of formula (I) where R a is a carbon-containing group optionally linked by oxygen, sulfur or nitrogen to the cyclohexyl ring and j is 1-10; and R and R* are independently but not simultaneously hydrogen or C(0)E where E is OR 1 4 or SR14 where R14 is hydrogen or alkyl of 1-6 carbon atoms; which process comprises treating an epoxide of Formula A with dimethyl sulfoxide and an alkali metal salt, wherein Formula A is: wherein E is OR14 or SR14 where R14 is hydrogen or alkyl of 1-6 carbon atoms; R a is the same as defined for Formula (I); and Y is Br, CI, F or I. 2. A process for preparing compounds of formula IA wherein: Rt is -(CR4R5)nC(0)0(CR4R5) m R6, -(CR4R5)nC(0)NR4(CR4R5) m R6, -(CR4R5) n O(CR4R5)mR6, or -(CR4R5) r R6 wherein the alkyl moieties are unsubstituted or substituted with one or more halogens; m is 0 to 2; n is 0 to 4; r is 0 to 6; R4 and R5 are independently selected hydrogen or Ct-2 alkyl; R6 is hydrogen, methyl, hydroxyl, aryl, halo substituted aryl, aryloxyCi-3 alkyl, halo substituted aryloxyC i-3 alkyl, indanyl, indenyl, C7-1 1 polycycloalkyl, tetrahydrofuranyl, furanyl, tetrahydropyranyl, pyranyl, tetrahydrothienyl, thienyl, tetrahydrothiopyranyl, thiopyranyl, C3.6 cycloalkyl, or a C4-6 cycloalkyl containing one or two unsaturated bonds, wherein the cycloalkyl or heterocyclic moiety is unsubstituted or substituted by 1 to 3 methyl groups, one ethyl group, or an hydroxyl group; provided that: a) when R(, is hydroxyl, then m is 2; or b) when R(, is hydroxyl, then r is 2 to 6; or c) when R6 is 2-tetrahydropyranyl, 2-tetrahydrothiopyranyl, 2-tetrahydrofuranyl, or 2-tetrahydrothienyl, then m is 1 or 2; or d) when R6 is 2-tetrahydropyranyl, 2-tetrahydrothiopyranyl, 2-tetrahydrofuranyl,or 2-tetrahydrothienyl, then r is 1 to 6; e) when n is 1 and m is 0, then R6 is other than H in -(CR4R5) n O(CR4R5) m 6; X is YR2; Y is O; X2 is O; R2 is -CH3 or -CH2CH3, optionally substituted by 1 or more halogens; R and R* are hydrogen or C(0)E wherein one of R or R* is always hydrogen and the other is always C(0)E where E is OR14, or SR14; W is a bond or is alkenyl of 2 to 6 carbon atoms or alkynyl of 2 to 6 carbon atoms; when W is a bond R' is hydrogen, halogen, C1 -4 alkyl, CH2NHC(0)C(0)NH2, halo-substituted C1-4 alkyl, CN, ORδ, CH2OR8, NRsRlO, CH2NR8R10, Z^H, C(0)OR8, or C(0)NR8Rlθ; and when W is alkenyl of 2 to 6 carbon atoms or alkynyl of 2 to 6 carbon atoms then R' is COOR14, C(0)NR4Ri4 or R7; R7 is -(CR4R5)qRi2 or Cj.g alkyl wherein the R12 or Ci .g alkyl group is unsubstituted or substituted one or more times by: methyl or ethyl unsubstituted or substituted by 1-3 fluorines, -F, -Br, -CI, -N0 2 , -NRι 0 Rι 1, -C(0)R8, -CO2R8, -0(CH 2 )2- 4 OR 8 , -0(CH 2 ) q R8, -CN, -C(O)NRι 0 Rl 1, -O(CH 2 ) q C(O)NRι 0 Rl 1, -0(CH 2 ) q C(0)R 9 , -NRi 0 C(0)NRioRl 1, -NRι 0 C(O)Rι 1, -NRι 0 C(O)OR9, -NRι 0 C(O)Rι 3 , -C(NRιo)NRιoRl l, -C(NCN)NRιoRl l, -C(NCN)SR9, -NRIQC(NCN)SR9 , -NRioC(NCN)NRi 0 Rl 1 , -NRi0S(O) 2 R9, -S(0) m 'R 9 , -NRι 0 C(O)C(O)NRι 0 Rl 1 , - NRιoC(0)C(0)Rιo, or R 1 ; q is 0, 1, or 2; Rl2 is R13, C3-C7 cycloalkyl, or an unsubstituted or substituted aryl or heteroaryl group selected from the group consisting of (2-, 3- or 4-pyridyl), pyrimidyl, pyrazolyl, (1- or 2-imidazolyl), pyπolyl, piperazinyl, piperidinyl, morpholinyl, furanyl, (2- or 3-thienyl), quinolinyl, naphthyl, and phenyl; R8 is independently selected from hydrogen or R9; R9 is C ι_4 alkyl optionally substituted by one to three fluorines; Rι θ is OR8 or Rι ι ; Ri j is hydrogen, or C 1.4 alkyl unsubstituted or substituted by one to three fluorines; or when Rio and R\ \ are as NRioRl 1 they may together with the nitrogen form a 5 to 7 membered ring comprised of carbon or carbon and one or more additional heteroatoms selected from O, N, or S; R 3 is a substituted or unsubstituted heteroaryl group selected from the group consisting of oxazolidinyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, tetrazolyl, imidazolyl, imidazolidinyl, thiazolidinyl, isoxazolyl, oxadiazolyl, and thiadiazolyl, and where R 13 is substituted on R u or R 13 the rings are connected through a carbon atom and each second R B ring may be unsubstituted or substituted by one or two Cι_2 alkyl groups unsubstituted or substituted on the methyl with 1 to 3 fluoro atoms; and R j 4 is hydrogen or Cj.g alkyl; which process comprises treating an epoxide of Formula A with dimethyl sulfoxide and an alkali metal salt; wherein X; 1X2; W; E; R'; R14 are the same as defined for Formula (IA); and Y is Br, CI, F or I. 3. The process of claim 2 wherein alkali metal salt is LiCl, KG, or NaCl and the reaction is carried out at between about 125-175 °C or 2-5 hours. 6. The process of claim 5 wherein, in the compound of formula A, W is a bond, R' is CN. 7. The process of claim 2, 3, 4, 5, or 6 wherein at 10-fold excess of dimethyl sulfoxide is used, the salt is sodium chloride and the reaction is heated to about 150 °C for about 3.5 hours. 8. A process for preparing an epoxide of Formula (A) wherein: R, is -(CR4R5)nC(0)0(CR4R5) m R6, -(CR4R5)nC(0)NR4(CR4R5) m 6, -(CR4R5) n O(CR4R5) m R6, or -(CR4R5) r R6 wherein the alkyl moieties unsubstituted or substituted with one or more halogens; m is 0 to 2; n is 0 to 4; r is 0 to 6; R4 and R5 are independently selected hydrogen or C 1-2 alkyl; R D is hydrogen, methyl, hydroxyl, aryl, halo substituted aryl, aryloxyCi-3 alkyl, halo substituted aryloxyCi-3 alkyl, indanyl, indenyl, C7-H polycycloalkyl, tetrahydrofuranyl, furanyl, tetrahydropyranyl, pyranyl, tetrahydrothienyl, thienyl, tetrahydrothiopyranyl, thiopyranyl, C3-6 cycloalkyl, or a C4-6 cycloalkyl containing one or two unsaturated bonds, wherein the cycloalkyl or heterocychc moiety is unsubstituted or substituted by 1 to 3 methyl groups, one ethyl group, or an hydroxyl group; provided that: a) when R6 is hydroxyl, then m is 2; or b) when R6 is hydroxyl, then r is 2 to 6; or c) when R6 is 2-tetrahydropyranyl, 2-tetrahydrothiopyranyl, 2-tetrahydrofuranyl, or 2-tetrahydrothienyl, then m is 1 or 2; or d) when R D is 2-tetrahydropyranyl, 2-tetrahydrothiopyranyl, 2-tetrahydrofuranyl,or 2-tetrahydrothienyl, then r is 1 to 6; e) when n is 1 and m is 0, then R6 is other than H in -(CR4R5) n O(CR4R5) rn R6; X is YR2; c) when R is 2-tetrahydropyranyl, 2-tetrahydrothiopyranyl, 2-tetrahydrofuranyl, or 2-tetrahydrothienyl, then m is 1 or 2; or d) when R D is 2-tetrahydropyranyl, 2-tetrahydrothiopyranyl, 2-tetrahydrofuranyl,or 2-tetrahydrothienyl, then r is 1 to 6; e) when n is 1 and m is 0, then R6 is other than H in -(CR4R5) n O(CR4R5) m R6; X is YR2; Y is O; X2 is O; W is a bond or is alkenyl of 2 to 6 carbon atoms or alkynyl of 2 to 6 carbon atoms; when W is a bond, R' is hydrogen, halogen, -4 alkyl, CH2NHC(0)C(0)NH2, halo-substituted -4 alkyl, CN, ORs, CH2OR8, NRsRlO, CH2NR8R10, C( ) {, C(0)ORs, or C(0)NRsRio; and when W is alkenyl of 2 to 6 carbon atoms or alkynyl of 2 to 6 carbon atoms, R' is R' is COOR14, C(0)NR4Ri4 or R7; R2 is -CH3 or -CH2CH3, optionally substituted by 1 or more halogens; and R7 is -(CR4R5)qRi2 or \.β alkyl wherein the R 2 or Cj.g alkyl group is unsubstituted or substituted one or more times by: methyl or ethyl unsubstituted or substituted by 1-3 fluorines, -F, -Br, -CI, -NO2, -NR IQR I \, -C(0)Rs, -CO2R8, -0(CH 2 )2- 4 OR 8 , -0(CH 2 ) q R8, -CN, -C(O)NRι 0 Rl 1, -O(CH 2 ) q C(O)NRι 0 Rl 1, -0(CH 2 ) q C(0)R 9 , -NRioC(O)NRioRn, -NRι 0 C(O)Rn, -NRι 0 C(O)OR 9 , -NRι 0 C(O)Rι 3 , -C(NRιo)NRιoRl 1, -C(NCN)NRιoRl l, -C(NCN)SR9, -NRιoC(NCN)SR9 , -NRlθC(NCN)NRιoRl 1, -NRι 0 S(O) 2 R9, -S(0) m 'R 9 , -NRι 0 C(O)C(O)NRι 0 Rl 1, - NRl 0 C(O)C(O)Ri0, or R 13 ; q is 0, 1, or 2; Rl2 is R13, C3-C7 cycloalkyl, or an unsubstituted or substituted aryl or heteroaryl group selected from the group consisting of (2-, 3- or 4-pyridyl), pyrimidyl, pyrazolyl, (1- or 2-imidazolyl), pyπolyl, piperazinyl, piperidinyl, morpholinyl, furanyl, (2- or 3-thienyl), quinolinyl, naphthyl, and phenyl; R8 is independently selected from hydrogen or R9; R9 is C j _4 alkyl optionally substituted by one to three fluorines; Rlo is OR δ or Rn; Ri j is hydrogen, or C 1.4 alkyl unsubstituted or substituted by one to three fluorines; or when R \ Q and Ri 1 are as NR10 11 they may together with the nitrogen form a 5 to 7 membered ring comprised of carbon or carbon and one or more additional heteroatoms selected from O, N, or S; which process comprises; treating a ketone of Formula (B) wherein X and R1X2 are the same as in Formula (A); with a lower alkyldihaloacetate in a polar aprotic solvent, and optionally saponifying the resulting alpha-haloepoxy ester. 9. The process of claim 8 wherein, in the compound of formula B, Ri is CH2- cyclopropyl, CH2-C5-6 cycloalkyl, or C4-6 cycloalkyl and R2 is Ci-2 alkyl unsubstituted or substituted by 1 or more halogens, the lower alkyldihaloacetate is lower alkyl dichloroacetate, and the base is an alkali metal t-butoxide. 10. The process of claim 9 wherein about 1.5 equivalent of the acetate and 1.5 equivalents of alkali metal t-butoxide are used. 11. The process of claim 10 wherein the acetate is methyl or ethyl dichloroacetate and the base is potassium t-butoxide. 12. The process of claims 8, 9, 10, and 11 wherein, in the compound of formula B, W is a bond and R' is CN or W is -C≡C-, Rj is cyclopentyl and R2 is CH3. 13. A process for enriching the cis form of a compound of Formula (IA) wherein: R! is -(CR4R5)nC(0)0(CR4R5) m R6, -(CR4R5)nC(0)NR4(CR4R5) m 6, -(CR4R5) n O(CR4R5) m R6, or -(CR4R5) r R6 wherein the alkyl moieties unsubstituted or substituted with one or more halogens; m is 0 to 2; n is 0 to 4; r is 0 to 6; wherein: Rl is -(CR4R5) n C(0)0(CR4R5) m R6, -(CR4R5)nC(0)NR4(CR4R5) m 6, -(CR4R5) n O(CR4R5) m R6 j or -(CR4R5) r R6 wherein the alkyl moieties unsubstituted or substituted with one or more halogens; m is 0 to 2; n is 0 to 4; r is 0 to 6; R4 and R5 are independently selected hydrogen or C i-2 alkyl; R D is hydrogen, methyl, hydroxyl, aryl, halo substituted aryl, aryloxyCi-3 alkyl, halo substituted aryloxyCi-3 alkyl, indanyl, indenyl, C7-1 1 polycycloalkyl, tetrahydrofuranyl, furanyl, tetrahydropyranyl, pyranyl, tetrahydrothienyl, thienyl, tetrahydrothiopyranyl, thiopyranyl, C3-6 cycloalkyl, or a C4-6 cycloalkyl containing one or two unsaturated bonds, wherein the cycloalkyl or heterocychc moiety is unsubstituted or substituted by 1 to 3 methyl groups, one ethyl group, or an hydroxyl group; provided that: a) when R6 is hydroxyl, then m is 2; or b) when R6 is hydroxyl, then r is 2 to 6; or c) when R is 2-tetrahydropyranyl, 2-tetrahydrothiopyranyl, 2-tetrahydrofuranyl, or 2-tetrahydrothienyl, then m is 1 or 2; or d) when Rg is 2-tetrahydropyranyl, 2-tetrahydrothiopyranyl, 2-tetrahydrofuranyl,or 2-tetrahydrothienyl, then r is 1 to 6; e) when n is 1 and m is 0, then R6 is other than H in -(CR4R5) n O(CR4R5) rn R6; X is YR2; Y is O; X2 is O; R2 is -CH3 or -CH2CH3, optionally substituted by 1 or more halogens; R and R* are hydrogen or C(0)E wherein one of R or R* is always hydrogen and the other is always C(0)E where E is OR14 or SR14 and R14 is hydrogen; W is a bond or is alkenyl of 2 to 6 carbon atoms or alkynyl of 2 to 6 carbon atoms; when W is a bond R' is hydrogen, halogen, C1-4 alkyl, CH2NHC(0)C(0)NH2, halo-substituted -4 alkyl, CN, ORs, CH2OR8, NRsRlO, CH2NR8R10, Z^H, C(0)OR8, or C(O)NRδRl0; and when W is alkenyl of 2 to 6 carbon atoms or alkynyl of 2 to 6 carbon atoms then R' is R' is COOR14, C(0)NR4Ri4 or R7; R7 is -(CR4R5)qRl2 or C \-6 alkyl wherein the R12 or Cj.g alkyl group is unsubstituted or substituted one or more times by: methyl or ethyl unsubstituted or substituted by 1-3 fluorines, -F, -Br, -CI, -N0 2 , -NRjo l l, -C(0)Rg, -CO2R8, -0(CH 2 )2- 4 OR 8 , -0(CH 2 ) q R 8 , -CN, -C(O)NRι 0 Ri 1, -O(CH 2 ) q C(O)NR 10 Ri 1, -0(CH 2 ) q C(0)R 9 , -NR 10C(O)NR 1 oR 1 1 , -NR ι 0 C(O)R 1 1 , -NR 1 0 C(O)OR 9 , -NR 1 0 C(O)R 13, -C(NRιo)NRιoRl l, -C(NCN)NRιoRl l, -C(NCN)SR9, -NRιoC(NCN)SR9 , -NRioC(NCN)NRi 0 Ri 1, -NRι 0 S(O) 2 R9, -S(0) m 'R 9 , -NRι 0 C(O)C(O)NRι 0 Rl 1, - NRi 0 C(O)C(O)Ri0, or Ri 3 ; q is 0, 1, or 2; Rl2 is R13, C3-C7 cycloalkyl, or an unsubstituted or substituted aryl or heteroaryl group selected from the group consisting of (2-, 3- or 4-pyridyl), pyrimidyl, pyrazolyl, (1- or 2-imidazolyl), pyπolyl, piperazinyl, piperidinyl, morpholinyl, furanyl, (2- or 3-thienyl), quinolinyl, naphthyl, and phenyl; R8 is independently selected from hydrogen or R9; R9 is Cι_4 alkyl optionally substituted by one to three fluorines; RlO is ORδ or Rn ; Rl 1 is hydrogen, or C 1.4 alkyl unsubstituted or substituted by one to three fluorines; or when RJO and Ri 1 are as NRioRl 1 they may together with the nitrogen form a 5 to 7 membered ring comprised of carbon or carbon and one or more additional heteroatoms selected from O, N, or S; Rl3 is a substituted or unsubstituted heteroaryl group selected from the group consisting of oxazolidinyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, tetrazolyl, imidazolyl, imidazolidinyl, thiazolidinyl, isoxazolyl, oxadiazolyl, and thiadiazolyl, and where R, 3 is substituted on R 12 or R, 3 the rings are connected through a carbon atom and each second R 13 ring may be unsubstituted or substituted by one or two Cj_2 alkyl groups unsubstituted or substituted on the methyl with 1 to 3 fluoro atoms; which process comprises treating the lower alkyl ester, lower alkyl thioester or mixed anhydride of Formula (IA) with an alkoxide base. 14. The process of claim 13 wherein the compound of formula IA, R\ is CH2- cyclopropyl, CH2-C5.6 cycloalkyl, or C4-6 cycloalkyl, R2 is Ci-2 alkyl unsubstituted or substituted by 1 or more halogens, the base is a alkali metel t-butoxide, and the reaction runs for 5-24 hours. 15. The process of claim 13 wherein the compound of formula I A is [4-cyano- 4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexane-l-carboxylic acid]. 16. The process of claim 13 wherein the base is potassium r-butoxide. 17. A compound which is lower alkyl 2-chloro-6-cyano-6-[3-(cyclopentyloxy)- 4-methoxyphenyl]- l-oxaspiro[2.5]octane-2-carboxylate. 18. The compound of claim 17 which is methyl 2-chloro-6-cyano-6-[3- (cyclopentyloxy)-4-methoxyphenyl]- l-oxaspiro[2.5]octane-2-carboxylate. 19. A compound which is 2-chloro-6-cyano-6-[3-(cyclopentyloxy)-4- methoxypheny 1]- 1 -oxaspiro[2.5]octane-2-carboxylic acid.

Inventors: DIEDERICH ANN M, NOVAK VANCE J, DIEDERICH, ANN, M., NOVAK, VANCE, J.
Applicants: DIEDERICH ANN M, NOVAK VANCE J, SMITHKLINE BEECHAM CORP, DIEDERICH, ANN, M., NOVAK, VANCE, J., SMITHKLINE BEECHAM CORPORATION
Application year: 2000
Main classification: C07C255
IPC codes: C07B53, C07C51, C07C61, C07C253, C07C255, C07D301, C07D303